| Colorado                                            | 0-31743                       | 84-1536517                                |
|-----------------------------------------------------|-------------------------------|-------------------------------------------|
| (State      or other jurisdiction of incorporation) | (Commission      File Number) | (IRS      Employer Identification Number) |
|                                                |                          |
| 1117      Herkimer Street, Houston, Texas           | 77008                         |
| (Address      of principal executive offices)       | (Zip      Code)               |

----

|   | INTERACTIVE      THERAPEUTICS, INC. |
|--------|-------------------------------------|

| Part      I  | Financial      Information |
|--------------|----------------------------|
|         |                       |   |   |
|         |                       |   |   |
|         | Item      1.               | Financial      Statements |   |
|         |                       |   |   |
|         |                       | Consolidated      Balance Sheets December 31, 2007 (unaudited) |   |
|         |                       |      and      March 31, 2007 | 3 |
|         |                       |   |   |
|         |                       | Consolidated      Statements of Operations (unaudited) |   |
|         |                       |     Three      and Nine Ended Months December 31, 2007 and 2006 |   |
|         |                       |     Inception      (February 15, 2005) through December 31, 2007 | 4 |
|         |                       |   |   |
|         |                       | Consolidated      Statements of Cash Flows (unaudited) |   |
|         |                       |     Nine      Months Ended December 31, 2007 and 2006 |   |
|         |                       |     Inception      (February 15, 2005) through December 31, 2007 | 5 |
|         |                       |   |   |
|         |                       | Notes      to Unaudited Consolidated Financial Statements | 6 |
|         |                       |   |   |
|         | Item      2.               | Management’s      Discussion and Analysis of Results of |   |
|         |                       |    Operations      and Financial Condition | 9 |
|         |                       |   |   |
|         | Item      3.               | Controls      and Procedures | 12 |
|         |                       |   |   |
| Part      II | Other      Information     |   |
|         |                       |   |   |
|         | Item      1.               | Legal      Proceedings | 13 |
|         |                       |   |   |
|         | Item      2.               | Unregistered      Sales of Equity Securities and Use of Proceeds | 13 |
|         |                       |   |   |
|         | Item      3.               | Defaults      Upon Senior Securities | 13 |
|         |                       |   |   |
|         | Item      4.               | Submission      of Matters to a Vote of Security Holders | 13 |
|         |                       |   |   |
|         | Item      5.               | Other      Information | 13 |
|         |                       |   |   |
|         | Item      6.               | Exhibits | 14 |
|         |                       |   |   |

----

|                                                                                                 |   |              |     |   |           |   |
|------------------------------------------------------------------------------------------------------|--------|-------------------|----------|--------|----------------|--------|
|                                                                                                 |   | December      31, |     |   | March      31, |   |
|                                                                                                 |   | 2007              |     |   | 2007           |   |
|                                                                                                 |   | (Unaudited)       |     |   |           |   |
| ASSETS                                                                                               |   |              |     |   |           |   |
|                                                                                                 |   |              |     |   |           |   |
| Current      assets:                                                                                 |   |              |     |   |           |   |
|     Cash      and cash equivalents                                               |   | $                 | --       |   |           | $      | -- |   |
| Total      assets                                                                                    |   | $                 | --       |   |           | $      | -- |   |
|                                                                                                 |   |              |     |   |           |   |   |   |
| LIABILITIES      AND SHAREHOLDERS' DEFICIT                                                           |   |              |     |   |           |   |   |   |
|                                                                                                 |   |              |     |   |           |   |   |   |
| Current      liabilities:                                                                            |   |              |     |   |           |   |   |   |
|     Accounts      payable and accrued expenses                                   |   | $                 | 136,500  |   |           | $      | 101,372 |   |
|     Convertible      notes payable                                               |   |              | 20,914   |   |           |   | 20,914 |   |
|         Total      current liabilities                       |   |              | 157,414  |   |           |   | 122,286 |   |
|                                                                                                 |   |              |     |   |           |   |   |   |
| Shareholders'      deficit:                                                                          |   |              |     |   |           |   |   |   |
|     Preferred      stock, no par value, 10,000,000 shares authorized,            |   |              | --       |   |           |   | -- |   |
|       no      shares issued or outstanding                             |   |              |     |   |           |   |   |   |
|     Common      stock, no par value, 500,000,000 shares authorized,              |   |              |     |   |           |   |   |   |
|       81,352,500      issued and outstanding at September 30, 2007 and |   |              |     |   |           |   |   |   |
|       March      31, 2007, respectively                                |   |              | 1,000    |   |           |   | 1,000 |   |
|     Deficit      accumulated in the developmental stage                          |   |              | (158,414 | )      |           |   | (123,286 | ) |
|          Total      shareholders’ deficit         |   |              | (157,414 | )      |           |   | (122,286 | ) |
| Total      liabilities and shareholders' deficit                                                     |   | $                 | --       |   |           | $      | -- |   |

----

|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   | Cumulative      from Inception |       |
|------------------------------------------------------------------------|--------|-------------------------------|---------------|--------|-----------------------------|--------|------------|----------------------------|--------|--------|------------------------|--------|--------|--------------------------------|------------|
|                                                                   |   |  Three      Months Ended |          |   |  Six      Months Ended |   |       | (February      15, 2005)to |   |
|                                                                   |   | December      31, 2007        |          |   | December      31, 2006      |   |       | December      31, 2007     |   |   | December      31, 2006 |   |   | December      31, 2007         |       |
|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |
| General      and administrative expenses                               |   | $                             | 11,211        |   |                        | $      | 11,211     |                       |   | $      | 33,663                 |   |   | $                              | 34,826     |   |   | $ | 155,226 |   |
|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
| Loss      from operations                                              |   |                          | (11,211       | )      |                        |   | (11,211    | )                          |   |   | (33,663                | )      |   |                           | (34,826    | ) |   |   | (155,226 | ) |
|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
| Other      income (expense)                                            |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
|   Interest      expense                                      |   |                          | (418          | )      |                        |   | (625       | )                          |   |   | (1,465                 | )      |   |                           | (1,167     | ) |   |   | (3,188 | ) |
|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
| Net      loss                                                          |   | $                             | (      11,629 | )      |                        | $      | (11,836    | )                          |   | $      | (35,128                | )      |   | $                              | (35,993    | ) |   | $ | (158,414 | ) |
|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
| Net      loss per share:                                               |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
|         Basic      and diluted |   | $                             | --            |   |                        | $      | --         |                       |   | $      | --                     |   |   | $                              | --         |   |   |   |   |   |
|                                                                   |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
| Weighted      average number of common shares                          |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
|   outstanding:                                               |   |                          |          |   |                        |   |       |                       |   |   |                   |   |   |                           |       |   |   |   |   |   |
|         Basic      and diluted |   |                          | 81,352,500    |   |                        |   | 81,352,500 |                       |   |   | 81,352,500             |   |   |                           | 81,352,500 |   |   |   |   |   |

----

|                                                                                    |   |                   |    |   | Cumulative      from Inception |   |
|-----------------------------------------------------------------------------------------|--------|------------------------|---------|--------|--------------------------------|--------|
|                                                                                    |   | Nine      Months Ended |    |   | (February      15, 2005)       |   |
|                                                                                    |   | December      31, 2007 |    |   | December      31, 2006         |   |   | to December      31, 2007 |   |
| Cash      flows from operating activities:                                              |   |                   |    |   |                           |   |   |   |   |
|     Net      loss                                                   |   | $                      | (35,128 | )      |                           | $      | (35,993 | ) |   | $ | (158,414 | ) |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Adjustments      to reconcile net loss to cash used in operatingactivities:             |   |                   |    |   |                           |   |   |   |   |   |   |   |
|    Changes      in assets and liabilities:                               |   |                   |    |   |                           |   |   |   |   |   |   |   |
|        Accounts      payable and accrued liabilities |   |                   | 35,128  |   |                           |   | 15,454 |   |   |   | 136,500 |   |
| Net      cash used in operating activities                                              |   |                   | --      |   |                           |   | (20,539 | ) |   |   | (21,914 | ) |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Cash      flows from investing activities                                               |   |                   | --      |   |                           |   | -- |   |   |   | -- |   |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Cash      flows from financing activities:                                              |   |                   |    |   |                           |   |   |   |   |   |   |   |
|     Proceeds      from issuance of convertible notes                |   |                   | --      |   |                           |   | 25,000 |   |   |   | 25,000 |   |
|     Repayment      of convertible notes payable                     |   |                   | --      |   |                           |   | -- |   |   |   | (4,086 | ) |
|     Collection      of stock subscription receivable                |   |                   | --      |   |                           |   | -- |   |   |   | 1,000 |   |
| Net      cash provided by financing activities                                          |   |                   | --      |   |                           |   | 25,000 |   |   |   | 21,914 |   |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Net      increase in cash                                                               |   |                   | --      |   |                           |   | 4,461 |   |   |   | -- |   |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Cash      and cash equivalents, beginning of period                                     |   |                   | --      |   |                           |   | 1,944 |   |   |   | -- |   |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Cash      and cash equivalents, end of period                                           |   | $                      | --      |   |                           | $      | 6,405 |   |   | $ | -- |   |
|                                                                                    |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Supplemental      cash flow information:                                                |   |                   |    |   |                           |   |   |   |   |   |   |   |
| Interest      paid                                                                      |   | $                      | --      |   |                           | $      | -- |   |   | $ | -- |   |
| Taxes      paid                                                                         |   | $                      | --      |   |                           | $      | -- |   |   | $ | -- |   |

----

----

----

|   | Recent      Sales of Unregistered Securities |
|--------|----------------------------------------------|

----

| Exhibit No. | Description                                                                                                                                                                                                                                       |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1         | Articles      of Incorporation (incorporated by reference to Exhibit 3.1 from      Registration Statement on Form–SB filed with the Securities and Exchange      Commission on October 11, 2000)                                            |
| 3.2         | Amended      Articles of Incorporation (filed herewith)                                                                                                                                                                                           |
| 3.3         | Bylaws      of Tabatha I, Inc. (incorporated by reference to Exhibit 3.2 from      Registration Statement on Form–SB filed with the Securities and Exchange      Commission on October 11, 2000)                                            |
| 4.1         | Specimen      of Stock Certificate (incorporated by reference to Exhibit 4.1 from      Registration Statement on Form–SB filed with the Securities and Exchange      Commission on October 11, 2000)                                        |
| 4.2         | Specimen      Class A Convertible Preferred Stock Certificate (incorporated by reference      to Exhibit 4.2 from Registration Statement on Form–SB filed with the      Securities and Exchange Commission on October 11, 2000)             |
| 14.1        | Code      of Ethics (incorporated by reference to Exhibit 14.1 to Registrant’s Form      10-KSB filed with the Securities and Exchange Commission June 29,      2005)                                                                       |
| 10.1        | Exchange      Agreement between Tabatha I, Inc. and Zigen, Inc. dated February 25, 2005      (incorporated by reference to Exhibit 10.1 to Registrant’s Form 8-K filed      with the Securities and Exchange Commission on May 31,    2005) |
| 10.2        | 2005      Amended and Restated Stock Option (incorporated by reference to Exhibit A      to Registrant’s Definitive Information Statement filed with the Securities      and Exchange Commission on July 1, 2005)                           |
| 21.1        | List      of Subsidiaries (filed herewith)                                                                                                                                                                                                        |
| 31.1        | Certification      pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act      of 1934, as amended (filed herewith)                                                                                                            |
| 32.1        | Certification      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of      the Sarbanes-Oxley Act of 2002 (filedherewith)                                                                                                  |

----